Philippe Duclos

Philippe Duclos

Auto-generated profile, based on publicly available information

Philippe Duclos

Department of Immunization, Vaccines and Biologicals, World Health Organization, 20 Ave Appia, CH-1211 Geneva 27, Switzerland

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2009 in BMC International Health and Human Rights
Verified
Journal Article
Open access
PDF file
PDPhilippe Duclos
Philippe Duclos
JOJean-Marie Okwo-Bele
Jean-Marie Okwo-Bele
MGMarta Gacic-Dobo
Marta Gacic-Dobo
TCThomas Cherian
Thomas Cherian
Vaccines have made a major contribution to public health, including the eradication of one deadly disease, small pox, and the near eradication of another, poliomyelitis.Through the introduction of new vaccines, such as those against rotavirus and pneumococcal diseases, and with further improvements in coverage, vaccination can significantly contribute to the achievement of the health-related United Nations Millennium Development Goals.The Global Immunization Vision and Strategy (GIVS) was developed by WHO and UNICEF as a framework for strengthening national immunization programmes and protect as many people as possible against more diseases by expanding the reach of immunization, including new vaccines, to every eligible person.This paper briefly reviews global progress and challenges with respect to public vaccination programmes. The most striking recent achievement has been that of reduction of global measles mortality from an estimated 750,000 deaths in 2000 down to 197,000 in 2007. Global vaccination coverage trends continued to be positive. In 2007 most regions reached more than 80% of their target populations with three doses of DPT containing vaccines. However, the coverage remains well short of the 2010 goal on 90% coverage, particularly in the WHO region of Africa (estimated coverage 74%), and South-East Asia, (estimated coverage 69%). Elements that have contributed to the gain in immunization coverage include national multi-year planning, district-level planning and monitoring, re-establishment of outreach services and the establishment of national budget lines for immunization services strengthening. Remaining challenges include the need to: develop and implement strategies for reaching the difficult to reach; support evidence-based decisions to prioritize new vaccines for introduction; strengthening immunization systems to deliver new vaccines; expand vaccination to include older age groups; scale up vaccine preventable disease surveillance; improve quality of immunization coverage monitoring and use the data to improve programme performance; and explore financing options for reaching the GIVS goals, particularly in lower-middle income countries. Although introduction of new vaccines is important,this should not be at the expense of sustaining existing immunization activities. Instead the introduction of new vaccine introduction should be viewed as an opportunity to strengthen immunization systems, increase vaccine coverage and reduce inequities of access to immunization services.


1 May 2004 in Vaccine
Verified
Journal Article
Closed access
PDPhilippe Duclos
Philippe Duclos

1 November 2013 in Vaccine
Verified
Journal Article
Open access
PDPhilippe Duclos
Philippe Duclos
LDLaure Dumolard
Laure Dumolard
NANihal Abeysinghe
Nihal Abeysinghe
AAAlex Adjagba
Alex Adjagba
CJCara Bess Janusz
Cara Bess Janusz
MÖMurat Hakan Öztürk
Murat Hakan Öztürk
The majority of industrialized and some developing countries have established National Immunization Technical Advisory Groups (NITAGs). To enable systematic global monitoring of the existence and functionality of NITAGs, in 2011, WHO and UNICEF included related questions in the WHO/UNICEF Joint Reporting Form (JRF) that provides an official means to globally collect indicators of immunization program performance. These questions relate to six basic process indicators. According to the analysis of the 2013 JRF, data for 2012, notable progress was achieved between 2010 and 2012 and by the end of 2012, 99 countries (52%) reported the existence of a NITAG with a formal legislative or administrative basis (with a high of 86% in the Eastern Mediterranean Region - EMR), among the countries that reported data in the NITAG section of the JRF. There were 63 (33%) countries with a NITAG that met six process indicators (47% increase over the 43 reported in 2010) including a total of 38 developing countries. 11% of low income countries reported a NITAG that meets all six process criteria, versus 29% of middle income countries and 57% of the high income ones. Countries with smaller populations reported the existence of a NITAG that meets all six process criteria less frequently than more populated countries (23% for less populated countries versus 43% for more populated ones). However, progress needs to be accelerated to reach the Global Vaccine Action Plan (GVAP) target of ensuring all countries have support from a NITAG. The GVAP represents a major opportunity to boost the institutionalization of NITAGs. A special approach needs to be explored to allow small countries to benefit from sub-regional or other countries advisory groups.

1 January 2003 in Journal of Hepatology
Verified
Journal Article
Closed access
PDPhilippe Duclos
Philippe Duclos

1 December 2012 in Vaccine
Verified
Journal Article
Closed access
PDP. Duclos
P. Duclos
David N DurrheimDavid N Durrheim
David N Durrheim
ARA.L. Reingold
A.L. Reingold
ZBZ.A. Bhutta
Z.A. Bhutta
KVK. Vannice
K. Vannice
HRH. Rees
H. Rees